New findings from a landmark clinical trial show that although certain gene variants may predict whether a person is likely to develop age-related macular degeneration (AMD), a potentially blinding eye disease that afflicts more than nine million Americans, these genes do not predict how patients will respond to Lucentis™ and Avastin™, the two medications most widel…
